Navigation Links
OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
Date:8/2/2009

's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that OPAXIO metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site,http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of our securities. Specifically, the risks and uncertainties that could affect the development of OPAXIO include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with OPAXIO in particular, including, without limitation, the potential for OPAXIO to be proved safe and effective (or to achieve response rates) for the trea
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
2. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
5. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
6. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
7. Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System
8. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
9. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
10. Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
11. IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aug. 1, 2014 Dyadic International, Inc. ("Dyadic") ... proprietary technologies are used to develop, manufacture and sell ... biopharmaceutical and industrial enzyme industries, announced today that it ... ended June 30, 2014 after market close on Thursday, ... that day at 5:00 p.m. Eastern Time to discuss ...
(Date:7/31/2014)... 1, 2014 Cipla ... heute bekannt, vor kurzem für OneDose ReadyfusOR™ ... nach chirurgischen Eingriffen eine kommerzielle Zusammenarbeit begonnen ... Union und weiterer europäischer Länder abdeckt. Cipla ... Ropivacain gefüllte OneDose ReadyfusOR später in diesem ...
(Date:7/31/2014)... STAAR Surgical Company (NASDAQ: STAA ) a ... delivery systems for the eye today reported revenue for ... million, a 10% increase over $18.2 million reported for ... basis, revenues grew 11% during the second quarter of ... effect of foreign currency exchange reduced sales by $0.1 ...
Breaking Medicine Technology:Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31
... FARMINGDALE, N.Y., Nov. 2, 2011 Misonix, Inc. ... company that designs, manufactures, and markets innovative therapeutic ... cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical ... Ultrasonic Bone Cutting System and the SonaStar® Ultrasonic ...
... 2011 Perrigo Company (Nasdaq: PRGO ; TASE) ... Drug Administration (FDA) a New Drug Application (NDA) for testosterone ... the owner of the Reference Listed Drug of its filing. ... the United States District Court for the District of New ...
Cached Medicine Technology:Misonix Announces its Exhibition at the European Association of Neurosurgical Societies 2Misonix Announces its Exhibition at the European Association of Neurosurgical Societies 3Perrigo Confirms Filing for Testosterone Gel 1.0% and Announcement of Patent Infringement Lawsuit by Abbott 2
(Date:8/2/2014)... Seattle, Wa (PRWEB) August 02, 2014 According ... Vkool.com, this is a comprehensive dating guide for women. The ... attract the man they want easily. The book also teaches ... commitment issues. , Vkool reveals in its review that ...     Chapter 1 – What’s Your Relationship Story? , ...
(Date:8/2/2014)... Lakewood Park Apartment Homes , located ... side, has undertaken a project that promises to help ... sense, while improving the “green” appearance of its already ... announced that Lakewood Park is currently preparing garden plots ... about being able to offer this opportunity to our ...
(Date:8/2/2014)... 02, 2014 When the Black Hat conventioneers ... this year, one thing can be always counted on, plenty ... as fear, uncertainty and doubt. The run-up has already ... article published by Reuters on July 31st about how ... or keyboard to successfully infect a system with malware, completely ...
(Date:8/1/2014)... 2014 Cannabis use among young people has ... to 17 having used marijuana at least once and 17 ... “Say ‘No’ to Drugs, Say ‘Yes to Life,’ volunteers from ... youth this summer with factual information about drugs, to help ... Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ to Life,” volunteers ...
(Date:8/1/2014)... brain plays a central role in regulating appetite and ... in the brain,s control of food intake and body ... process has been unclear. A new study ... that PPARγ activity in a type of neuron known ... response to high-fat diet. Sabrina Diano and colleagues ...
Breaking Medicine News(10 mins):Health News:Girl Gets Ring System Review Exposes Jonathan Green's Dating Guide For Women – Vkool.com 2Health News:Girl Gets Ring System Review Exposes Jonathan Green's Dating Guide For Women – Vkool.com 3Health News:Lexington’s Lakewood Park Apartments Getting Into Gardening 2Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 2Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 3Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 4Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 5Health News:Addressing a Serious Issue Affecting German Teens 2
... committee Sunday said medicines sold in shops would indicate ... 2. ,The decision was taken in a meeting ... of chemicals, fertilizers and steel. The members were discussing ... members decided that the 354 drugs in the national ...
... is where the Codex Alimentarius Commission’s role is crucial. If ... uphill task to maintain standards in taste and safety. ... to the European community. This is indeed a combined worthy ... Agriculture Organization of the United Nations. ,They are ...
... The government has planned to alter citeria for jobless benefit ... illness under //reforms being unveiled this week. ,Work and ... off benefit and into work following the publishing of his ... the personal capability assessment which is used to decide whether ...
... Recently an UCLA study by a team of researchers ... carotid atheromas formation in patients //at a higher risk ... link may be due to blockages containing calcium in ... carotid artery. ,These blockages, or atheromas, contain ...
... the disease strides ahead with greater determination from obscurity to ... why is the pandemic// outpacing us, or are countries acting ... million people and affected another 40 million worldwide? ... York for the review meeting to the United Nations General ...
... consider Medical Council of India seniority on appointment in ... ,Talking to reporters here Association General Secretary, ... about 34,000 doctors are unemployed in India in which ... is recruiting doctors for government health services, the government ...
Cached Medicine News:Health News:AIDS: Why the pandemic outpaces us 2Health News:AIDS: Why the pandemic outpaces us 3
... has been designed for use with Bioneer's ... can handle 96 samples (Plasmid DNA, Genomic ... and purification. While conventional kits use centrifugal ... BioVac 96 Vacuum Manifold uses vacuum pressure ...
Plastic Tray Type Vacuum Manifold...
... manifold is designed to efficiently process ... holds one deep well plate and ... are drawn through the wells ... microplates. The base holds and ...
QIAvac 96 is designed for efficient processing of QIAGEN 96-well plates....
Medicine Products: